| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | PRE 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | NOVABAY PHARMACEUTICALS, INC. |
| Entity Central Index Key | 0001389545 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | |
| Dec. 31, 2022 | Dec. 31, 2021 | |
| Pay vs Performance Disclosure [Table] | ||
| Pay vs Performance [Table Text Block] | P AY ERSUS ERFORMANCE As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, the Company is providing the following disclosure about the relationship between executive pay actually paid (as defined by SEC rules) and the Company’s financial performance. Pay-Versus-Performance Table In accordance with the SEC’s rules, the below table sets forth the following information for the fiscal years ended December 31, 2022 and 2021: (1) the total compensation paid to the Company’s principal executive officer, the CEO, and the non-CEO NEOs, as provided on the “Summary Compensation Table” provided elsewhere in this Proxy Statement; (2) the compensation “actually paid” to the CEO and the non-CEO NEOs, which reflects certain adjustments based on SEC rules and as described in the footnotes below; (3) the Company’s total stockholder return (“ TSR Fiscal Year Summary CEO (1) Compensation Actually Paid Total - CEO (2) Summary Non-CEO NEO (3) Compensation Actually Paid Total Non-CEO NEOs (4) NBY TSR (5) Fiscal Year Net Loss (in (6) 2022 $ 364,954 $ 111,489 $ 259,285 $ 108,806 $ (45.97 ) $ (10,608 ) 2021 $ 795,521 $ 490,901 $ 528,704 $ 422,207 $ (46.04 ) $ (5,824 ) (1) Reflects compensation amounts reported in the “Summary Compensation Table” for the CEO, Mr. Hall. (2) Compensation actually paid (as defined by SEC rules) to the CEO for each period presented reflects the amount set forth in column (1), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table. (3) Dr. Audrey Kunin, our Chief Product Officer, and Mr. Jones, our former Chief Financial Officer, were our non-CEO NEOs in fiscal years 2022 and 2021. Dr. Audrey Kunin was appointed our Chief Product Officer effective November 5, 2021, and therefore only received partial compensation in fiscal year 2021. Due to Dr. Audrey Kunin’s partial year service in fiscal year 2021, the 2021 amount represents a weighted-average (based on the number of days Dr. Audrey Kunin and Mr. Jones served). (4) Average compensation actually paid (as defined by SEC rules) to the Company’s NEOs (except the CEO) for each period presented reflects the amount set forth in column (3), adjusted as set forth below in the Reconciliation of Compensation Actually Paid Table. (5) Reflects the TSR of a $100 investment in the Company from the beginning of fiscal year 2021 through each of the fiscal years ended December 31, 2022 and 2021. The Company’s TSR includes share price depreciation, but does not include dividend reinvestment as the Company did not pay any dividends in the 2022 or 2021 fiscal years. (6) Reflects “Net loss” in the Company’s Consolidated Statements of Operations and Comprehensive Loss included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. | |
| PEO Total Compensation Amount | $ 364,954 | $ 795,521 |
| PEO Actually Paid Compensation Amount | $ 111,489 | 490,901 |
| Adjustment To PEO Compensation, Footnote [Text Block] | Reconciliation of Compensation Actually Paid Table The following table details the applicable adjustments that were made to determine compensation actually paid (all amounts are weighted-averages for the NEOs other than the CEO Reporting Reported ($) Deduct: ($) (a) Add: Equity ($) (b) Deduct: ($) (c) Add: ($) (c) Compensation ($) CEO 2022 $ 364,954 $ — $ (253,465 ) $ — $ — $ 111,489 2021 795,521 (395,000 ) 90,380 — — 490,901 NEOs (except the Chief Executive Officer) 2022 $ 259,285 $ — $ (150,479 ) $ — $ — $ 108,806 2021 528,704 (206,308 ) 100,500 — — 422,207 (a) As provided in the “Summary Compensation Table” and elsewhere in this Proxy Statement, no equity awards were granted to any NEO in the 2022 fiscal year. For the 2021 fiscal year, the reported value of equity awards represents the grant date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for each applicable period. (b) The equity award adjustments for each applicable period include the addition (or subtraction, as applicable) of the following (all amounts are weighted averages for the NEOs other than the Chief Executive Officer): Reporting Period-end fair ($) Period-over- ($) Fair value as awards ($) Period-over- ($) Fair value at the end of the prior period of equity awards that failed to meet vesting conditions in the period ($) Value of dividends or other earnings paid on stock or option awards not otherwise reflected in fair value or total compensation ($) Total equity award adjustments ($) CEO 2022 $ — $ (236,113 ) $ — $ (17,352 ) $ — $ — $ (253,465 ) 2021 190,004 (86,857 ) — (12,767 ) — — 90,380 NEOs (except the Chief Executive Officer) 2022 $ — $ (134,736 ) $ — $ (15,743 ) $ — $ — $ (150,479 ) 2021 104,840 (56,346 ) — 52,006 — — 100,500 (c) In the periods presented and consistent with the “Summary Compensation Table”, the Company did not have: (i) a change in the actuarial present value of the accumulated benefit under any defined benefit or actuarial pension plans or (ii) any service cost or prior service cost related to any defined benefit or actuarial pension plans. | |
| Non-PEO NEO Average Total Compensation Amount | $ 259,285 | 528,704 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 108,806 | 422,207 |
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Pay-Versus-Performance Relationship The Company believes the table above shows the alignment between compensation actually paid to the CEO and our other non-CEO NEOs and the Company's performance. The charts below show, for the past two years, the relationship of the CEO and the other non-CEO NEOs compensation “actually paid” and (i) the Company's TSR and (ii) the Company's net loss. | |
| Total Shareholder Return Amount | $ (45.97) | (46.04) |
| Net Income (Loss) | (10,608,000) | (5,824,000) |
| PEO Reported Summary Compensation Total [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 364,954 | 795,521 |
| PEO Add Equity award adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (253,465) | 90,380 |
| PEO Compensation actually paid [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 111,489 | 490,901 |
| PEO Deduct Reported value of equity awards [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (395,000) | |
| NEO Reported Summary Compensation Total [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 259,285 | 528,704 |
| NEO Add Equity award adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (150,479) | 100,500 |
| NEO Compensation actually paid [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 108,806 | 422,207 |
| NEO Deduct Reported value of equity awards [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (206,308) | |
| PEO Period-over-period change in fair value of outstanding and unvested equity awards [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (236,113) | (86,857) |
| PEO Period-over-period change in fair value of equity awards granted in prior periods that vested in the period [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (17,352) | (12,767) |
| PEO Total equity award adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (253,465) | 90,380 |
| PEO Period-end fair value of equity awards granted during the period [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | 190,004 | |
| NEO Period-over-period change in fair value of outstanding and unvested equity awards [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (134,736) | (56,346) |
| NEO Period-over-period change in fair value of equity awards granted in prior periods that vested in the period [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | (15,743) | 52,006 |
| NEO Total equity award adjustments [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | $ (150,479) | 100,500 |
| NEO Period-end fair value of equity awards granted during the period [Member] | ||
| Pay vs Performance Disclosure [Table] | ||
| Adjustment to Compensation Amount | $ 104,840 | |
